Literature DB >> 9868994

Lowering the risk of neuropathy, foot ulcers and amputations.

A J Boulton1.   

Abstract

Peripheral neuropathy is one of the most common long-term complications of Type 2 diabetes. A population-based study in the north of England showed that 42% of Type 2 diabetic patients had clinical evidence of neuropathy. The Diabetes Control and Complications Trial (DCCT) has shown that the incidence of neuropathy in Type 1 diabetes can be reduced by over 50% with intensive therapy and optimal glycaemic control. Hyperglycaemia is believed to be a major aetiological factor in the development of neuropathy in Type 2 diabetes. Neuropathy cannot be diagnosed through history alone; therefore, careful examination of the feet for evidence of sensory loss and an assessment of the circulation must form part of the annual review of each patient. Peripheral somatic and autonomic neuropathy, together with peripheral vascular disease, are major contributing factors to the development of foot ulcers. In addition, abnormalities of foot shape (e.g. claw toes, prominent metatarsal heads) and the presence of plantar callus are signs of foot-ulcer risk. Effective patient education can reduce the incidence of foot ulceration and amputation by over 50%; therefore, all patients with a high risk of foot ulcers should be informed and, if indicated, referred for regular podiatry. The team approach to diabetic foot problems is an effective method of providing treatment for active ulcers. This should be followed by appropriate education, the provision of follow up and if indicated, suitable footwear and hosiery. Key members of the team are the podiatrist, the specialist nurse and the orthotist; medical staff may include the diabetologist and a vascular or orthopaedic surgeon. Thus, the risk of foot ulceration and amputation can be reduced by careful screening and patient education, without the need for expensive equipment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868994     DOI: 10.1002/(sici)1096-9136(1998120)15:4+<s57::aid-dia741>3.3.co;2-4

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  18 in total

Review 1.  Model-based evaluation of diabetic foot prevention strategies in Austria.

Authors:  Marion S Rauner; Kurt Heidenberger; Eva-Maria Pesendorfer
Journal:  Health Care Manag Sci       Date:  2005-11

Review 2.  Screening for the high-risk foot of ulceration: tests of somatic and autonomic nerve function.

Authors:  Vasiliki Argiana; Ioanna Eleftheriadou; Nicholas Tentolouris
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

3.  Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.

Authors:  Angelika Bierhaus; Karl-Matthias Haslbeck; Per M Humpert; Birgit Liliensiek; Thomas Dehmer; Michael Morcos; Ahmed A R Sayed; Martin Andrassy; Stephan Schiekofer; Jochen G Schneider; Jörg B Schulz; Dieter Heuss; Bernhard Neundörfer; Stefan Dierl; Jochen Huber; Hans Tritschler; Ann-Marie Schmidt; Markus Schwaninger; Hans-Ulrich Haering; Erwin Schleicher; Michael Kasper; David M Stern; Bernd Arnold; Peter P Nawroth
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 4.  Exercise intervention studies in patients with peripheral neuropathy: a systematic review.

Authors:  Fiona Streckmann; Eva M Zopf; Helmar C Lehmann; Kathrin May; Julia Rizza; Philipp Zimmer; Albert Gollhofer; Wilhelm Bloch; Freerk T Baumann
Journal:  Sports Med       Date:  2014-09       Impact factor: 11.136

Review 5.  Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes.

Authors:  Caitlin W Hicks; Elizabeth Selvin
Journal:  Curr Diab Rep       Date:  2019-08-27       Impact factor: 4.810

6.  Addressing Health Literacy and Numeracy to Improve Diabetes Education and Care.

Authors:  Richard O White; Kathleen Wolff; Kerri L Cavanaugh; Russell Rothman
Journal:  Diabetes Spectr       Date:  2010-10-02

Review 7.  Diagnosis and management of diabetic neuropathy.

Authors:  Bruce A Perkins; Vera Bril
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 8.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 9.  Evidence-based management of peripheral vascular disease.

Authors:  Nicolas W Shammas; Eric J Dippel
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

10.  The Neuropad test: a visual indicator test for human diabetic neuropathy.

Authors:  C Quattrini; M Jeziorska; M Tavakoli; P Begum; A J M Boulton; R A Malik
Journal:  Diabetologia       Date:  2008-03-27       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.